Epigral Limited reported its highest-ever quarterly revenue of ₹736 crore for Q4 FY2026, marking a 22% growth compared to the previous quarter. Driven by a 15% sequential increase in sales volume and improved realizations, the company achieved an EBITDA of ₹169 crore with a margin of 23%. Despite global uncertainties, the company continues its strategic transition toward high-growth derivatives and specialty chemicals, supported by ongoing infrastructure projects and a diversified product portfolio.
Financial Growth Highlights
For the quarter ending March 2026, Epigral Limited delivered a strong financial performance, recording ₹736 crore in revenue. This growth was fueled by robust demand and a full recovery in operations following scheduled maintenance in the previous quarter. The company’s focus on operational efficiency is reflected in the 64% growth in absolute EBITDA, which rose to ₹169 crore, while Profit After Tax (PAT) surged by 109% to ₹82 crore compared to the preceding quarter.
Strategic Shift Toward Specialty Chemicals
Epigral continues to execute its long-term strategy of transitioning toward a higher-value product mix. Derivatives and specialty chemicals accounted for 54% of revenue in Q4 FY2026, up from 52% in the prior quarter. The company aims to further increase this segment’s contribution to approximately 70% by FY2028, moving away from its traditional reliance on the chlor-alkali business.
Capex and Expansion Milestones
The company maintains a strong growth trajectory through its ongoing capital expenditure plans. In FY2026, Epigral invested ₹394 crore into expanding its production capabilities. Key projects include increasing CPVC Resin capacity to 1,50,000 TPA and Epichlorohydrin capacity to 1,00,000 TPA. These initiatives, expected to be commissioned in H1FY27, are designed to meet India’s growing domestic demand, promote import substitution, and strengthen the company’s fully integrated manufacturing complex.
Commitment to Sustainability and Governance
Epigral has reinforced its commitment to sustainable growth, recently receiving the EcoVadis Silver Medal and renewing its Responsible Care certification for another 3 years. The company is actively integrating green energy into its operations, including the development of a 38.14 MW Wind-Solar Hybrid Power Plant to support internal consumption. These efforts, combined with a technically qualified leadership team, ensure that the company remains well-positioned to deliver long-term value to its stakeholders.
Source: BSE
